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Parkinson’s disease (PD) is a complex multigenic neurodisorder frequently occurring in elderly persons. To investigate noncoding
tiny microRNA mediated gene regulation, miRanda (version 1.0b) was used to predict human miRNA target sites on selected 29
genes related to PD. To verify output generated from miRanda, a similar analysis was performed only for microRNA target sites in
3 UTR using TargetScan (version 5.1). Data extracted by miRanda elucidates the mode of microRNA action based on the location
oftargetsitesintheParkinsongenes.SitespronetoactionofmultiplemiRNAswereidentiﬁedas“hotspots.”Importantproperties
of each miRNA including multiplicity and cooperativity appear to contribute towards a complex interplay between miRNAs and
their targets. Two sets of predicted results were explored for the occurrence of target sites of 112 miRNAs expressed in midbrain.
Overall, convergence of results predicted by two algorithms revealed that 48 target sites for midbrain-speciﬁc miRNA occur in
close proximity in 9 genes. This study will pave a way for selection of potential miRNA candidates for Parkinson’s disease-related
genes for quick therapeutic applications and diagnosis.
Copyright © 2009 Shinde Santosh P. et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Mysteries underlying the neurological disorders are as com-
plex and bewildering as human mind itself. Aging related
disorders such as Alzheimer and Parkinson’s diseases are
major culprits behind poor memory in elderly persons.
Parkinson’sdiseasehasemergedasthesecondmostcommon
neurodegenerative disorder aﬄicting about 4 million people
across the globe [1]. Steep rise in PD cases in aged
population is quite distressing [2]. Though sporadic cases
are more common yet in a signiﬁcant fraction of western
population, it can be attributed to delicate and ﬁne tuning
of gene regulation proﬁle related to disorders [3]. PD is
manifested as an outcome of interaction of copious genetic
and environmental factors [4].
Parkinson’s disease is characterized by motor impair-
ments such as tremor of a limb usually restricted to one
side of body. Concomitant symptoms including rigidity or
stiﬀness of the limbs and trunk, akinesia, and impaired
balance and postural instability [5–8] are often accompanied
with depression to complete the clinical picture of PD. Onset
of symptoms is the result of loss of neurons substantia nigra
pars compacta causing a considerable decline in levels of
Dopamine, a neurotransmitter. The hallmarks essential for
PD diagnosis is the occurrence of eosinophilic proteinaceous
inclusions, Lewy bodies in extant dopaminergic neurons. PD
is incurable and various drugs prescribed for PD treatment
oﬀer merely symptomatic relief and contribute little to the
halt of disease progression.
Since its description in 1817, very little was known about
its etiology until recent days. The discovery of a series of
genes involved in rare familial PD has instilled immense
exhilaration and provided much needed impetus to research
in this arena. There is mounting evidence that several
geneslikea-synuclein,Parkin,PTENinducedputativekinase
1 (PINK1), DJ-1, leucine-rich repeat kinase 2 (LRRK2),
and ATP13A2 are misregulated in PD [9]. But whether
these genes contribute in a common regulatory pathway or2 Journal of Biomedicine and Biotechnology
multiple parallel subpathways converging to same sequence
in molecular pathogenesis of PD is yet to be resolved.
microRNAs, generally known as negative regulators of gene
expression, have attracted a lot of attention in recent times
for their possible role on ﬁne tuning of disease related
genes. miRNAs are known to regulate approximately 30% of
genes in human genome [10]. There is escalating evidence
regarding the involvement of the abundant and endogenous
21–23nt long RNA in various neurodegenerative disorders.
Elucidation of precise biological function of these miRNAs
hasbeenthesubjectofmanystudies.miRNAsareinvolvedin
cell diﬀerentiation, development, apoptosis [11], stress resis-
tance [12], tumor formation [13], and more importantly in
neurodegenerative disorders [11, 14–16]. The establishment
of role of miR-133b in mammalian midbrain dopaminergic
neurons (DNs) has spurred a new interest in studies of
the prospective function of these miRNAs in Parkinson’s
disease [17]. It appears that level of several miRNAs (miR-
10a, miR-10b, miR-212, miR-132, and 495) modulates genes
related to PD considerably [18]. Earlier studies provide some
evidences about the involvement of miRNAs in Parkinson
disease [19]b u td on o to ﬀer a full comprehensive view of
microRNA dependent regulation of PD genes. Availability
of simple, rapid, and accurate computer-based methods
and development of eﬃcient algorithms for micro RNA
prediction have generated a great deal of interest [20, 21].
Here, our analysis reveals a complex interplay between
microRNA and Parkinson genes for understanding the
mechanism of PD pathogenesis. In practice, conventional
biochemicalmiRNAproﬁleisoftenencounteredwithseveral
problems including transient, and low level of microRNA
expression, tissue speciﬁcity and complex interaction with
targets [20, 22]. Computational prediction of miRNA target
sites can readily predict the role of miRNAs in the regulatory
pathways.
The multifarious relationships shared by genes related
to PD pathway, regulation of various miRNAs by other
miRNAs in response to indeﬁnite cues impose the need
of an interaction map. This study aims at developing a
complex interaction map between genes and microRNAs in
the PD pathways, which will provide readymade clues for
selection of miRNA using a comprehensive view of overall
interplay between genes and microRNAs. This interaction
map unravels some unexpected complexity in searching of
microRNA target selection.
2. Methods
In the current study, we emphasized on identiﬁcation of
fraction of miRNA speciﬁc to the PD genetic pathway
and propose an interaction network between these genes
and targeted miRNA. Figure 1 represents stepwise workﬂow
undertaken for the study.
2.1. Selection of Genes. Parkinson’s disease pathway
(Figure 2) in Kyoto Encyclopedia of genes and Genomes
(KEGG) available at http://www.genome.jp/kegg/ consists
of 27 genes. Among them, genetic studies have identiﬁed
few candidates such as parkin (PARK5, PARK6, PARK7,
PARK8), alpha-syncline, NR4A2, synphilin-1, GBA, SNCA
which, once mutated, can result Parkinson’s disease like
symptoms. Here, 2 more genes were also added to the PD
network based on literature survey.
Genes selected are CASP3, CASP9, COX6B2, CYCS,
GPR37, HTRA2, APAF1, UQCRFSL1, LOC100133737,
LRRK2, NDUFS7, PARK2, PARK7, PTEN induced puta-
tive kinase1 (PINK1), SDHA, SEPT5, SLC6A3, SLC18A1,
SLC25A4, SNCA, SNCAIP, TH, UBE1, UBE2J2, UBE2L3,
ubiquitinB, UCHL1, GBA [23–25], NR4A2 [26]. Out of the
29 genes selected for this study, PINK1, PARK7, UBE2J2,
GBA, and CASP9 are located on chromosome 1 while
UCHL1, SNCA, CASP3, SLC25A4 are located on chromo-
some4.GenesSDHA,SLC6A3,SNCAIParepresentonchro-
mosome 5. The position and location of each gene on the
chromosomes is summarized (see Table S1 in Supplemen-
tary Material available online at doi:10.1155/2009/363145).
Sequences for the selected genes were collected in Fasta
format from NCBI.
Total 866 human miRNA were downloaded in Fasta for-
mat from miRBASE (http://microrna.sanger.ac.uk/sequen-
ces/).
ForpredictionofmiRNAtargets,miRanda(version1.0b)
employs dynamic programming based on sequence comple-
mentarity, allotting higher weights to matches at the 5  end
of the mature miRNA while considering the free energy of
the RNA-RNA duplex (calculated using RNAFold) [27]a n d
the extent of conservation of the miRNA target across related
genomes. miRanda [28, 29] softwareversion 1.0b available at
http://www.microrna.org/miranda was employed to predict
target sites for these miRNAs. Cut-oﬀ values for prediction
of target sites selected in analysis were Gap Open Penalty:
2.0, Gap Extend: 8.00 match score (S) ≥150.00, duplex
free energy (ΔG) = −25.00kcal/mol, Scaling Parameter (w)
= 3.00. The selected gene sequences and human miRNA
sequences were used as reference and query sequences,
respectively,asinputtomiRanda.Conservationcriterionwas
not used as it is reported that the nonconserved target sites
may also play a part in repression.
Output generated from miRanda was used for target site
identiﬁcation and subsequent analysis. Top 10 microRNAs
were selected based on the highest threshold match scores.
Multiplicity and cooperativity were determined for all the
miRNAs. Positions of the target sites for these miRNAs on
29 genes were explored and sites prone to multiple miRNAs
were identiﬁed. After assembling the data for all genes, top
10 miRNAs were selected based on high multiplicity and
ClustalW provided in miRBase was employed to investigate
the conservation pattern in these microRNAs. A complex
interaction map of interplay among 29 genes and top 10
miRNAs which showed maximum number of interaction
with Parkinson disease associated genes was constructed.
2.2. Physico-Chemical Properties of Top 10 miRNAs. Impor-
tant physico-chemical properties of 10 miRNAs (based on
multiplicity) such as molecular weight (Kilo Dalton), free
energy(δGinKcal/mol),andcompositionwerecalculatedbyJournal of Biomedicine and Biotechnology 3
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Figure 1: Schematic representation of the workﬂow.
employingOligoCalc:OligonucleotidePropertiesCalculator
[30].
Molecular weight and free energy were calculated by the
following formulae:
Molecular weight (Mw) = (Anx 329.21) +(Un x 306.17)
+(Cn x 305.18) +(Gn x 329.21)
+ 159.0,
(1)
where An, Un, Cn and Gn are the number of each respective
nucleotide of the RNA molecule under consideration. Addi-
tionally, weight 159.0gm/mole was added that accounts to
5 triphosphat.
Free energy (δG) : δG = RT ln

RNA ·template

(RNA)

template


. (2)
Both (1)a n d( 2) assume that the annealing occurs under the
standard conditions of 50nM primer, 50mM Na+, and pH
7.0.
2.3. Validation of miRNA Target Prediction Using Multiple
Programmes. I no r d e rt ov e r i f yt a r g e ts i t e so fm i c r o R N A
predicted solely by miRanda, TargetScan (Release 5.1) (31)
was employed for prediction of target sites. miRNA targets
in 3 UTR that are common in two miRNA prediction
algorithms and their comparative analysis was provided.
Information regarding speciﬁc microRNAs that
are expressed in midbrain was collected from WALK
database (http://web.bioinformatics.ic.ac.uk/MSc07/WALK/
mirna.html) and whole data was screened for target sites of
midbrain-speciﬁc miRNAs.
3. Results and Discussion
Complex interplay of genes and miRNA appears to be a
key factor in determining the delicate balance of disease
controlling genes expression. Prediction of miRNAs using
computer-based methods serves many advantages and aid in
recognition of molecular hallmarks of the disease that can
lead to development of eﬀective screens for miRNA targets.
However, prediction of microRNA targets might suﬀer
fromnumerousproblemsincludingtissuespeciﬁcexpression
and lack of validation. Such weakness of in silico studies
can be partially compensated by predicting targets using
multiple programmes. The outputs can be eﬀectively utilized
for development of a molecular marker in diagnosis and
prognosis.
3.1. miRNA Target Sites in Parkinson’s Disease. Total 5501
miRNA binding target sites were predicted for 29 genes
selected and the dataset of 866 human miRNA used for the
analysis.
Initially, top 20 miRNA targets were selected on basis
of top scores and stringent parameters for each gene. These
sites were distributed diversely in 5 untranslated regions;
coding region and 3 untranslated regions (UTR) (Figure 3,
Figure SF1-29, and Table S2 in Supplementary Material).
Surprisingly, more target sites were predicted in CDS region
as compared to 3 UTR and 5 UTR. It was found that
target sites predicted for CASP3, COX6B2, CYCS, SEPT5,
SLC6A3, UBE2J2, UBE2L3 genes were more in 3 UTR. In
contrast, no target was predicted in 3 UTR for GPR37,
PINK1, SLC25A4, UQCRFSL1, LOC100133737 genes. Till
recently it was believed that microRNA can target all the
regions including 5 UTR, CDS, and 3  UTR in plants and
are restricted to 3 UTR in animals. But there is growing4 Journal of Biomedicine and Biotechnology
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Figure 2: Pathway showing genes involved in Parkinson’s disease (Courtesy: KEGG pathway).
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Figure 3: Distribution of predicted target sites in 5 UTR, CDS and
3 UTR as predicted using miRanda.
evidence that micro RNA can target the CDS [31–35]a s
well as 5 region [35, 36]. Location of target sites in a
speciﬁed region also provides clues about mode of action
of microRNAs, whether they are involved in transcriptional,
posttranscriptional, and translational inhibition. Figure 4
shows the distribution pattern of miRNA target sites on the
NDUFS7 genes.
3.2. Identiﬁcation of Hotspots. Many microRNAs share either
same target sites or sites located in vicinity of other
microRNAs. Gathering of many miRNAs in the same site
or vicinity area is commonly known as “hotspot.” Usually,
miRNAs that occupy the same spot are coregulated and
coexpressed[37,38]andareinvolvedinimportantbiological
functions [39–41]. In contrast, it is reasonable to anticipate
that sequences in hotspot region might be occupied only
by a predominant microRNA among the cluster members
and a microRNA having aﬃnity towards such sites may
outcast other microRNAs by competitive selection. But
how such selection of single microRNA occurs is still
unknown. This may provide a reasonable clue regarding
the variable eﬀectiveness of microRNA pools. Researchers
employ diﬀerent criteria for deﬁning cluster, mostly ranging
from the presence of more than two miRNAs in a same
chromosomal sites [36]o c c u r r e n c ei ns a m eo r i e n t a t i o n ,Journal of Biomedicine and Biotechnology 5
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Figure 4: Schematic representation of miRNA targets on NDUFS7.
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Targetscan, where datalabels show the number of target sites
predicted for each gene.
absence of interfering transcription unit [42]o ri ns o m e
cases on the basis of phylogenetic relationships [37]. Keeping
in view, the coannotation of these spots in important
biological processes, 5501 miRNA targets were then further
analyzed for identifying target prone regions in all Parkinson
associated genes.
In the present study, we employed some preset criteria,
which deﬁne a region as a hotspot if the region showed
minimum 10 nucleotide overlap at starting position and
possesses minimum overlapping ﬁve miRNA targets (see
Supplementary Material). Total 288 regions were identiﬁed
on all 29 genes spanned across 5 UTR, 3 UTR, and coding
regions of the genes (Figure SF30-57 in supplement). Among
all miRNA hotspots, 81, 77, and 130 regions were found
in 5 UTR, 3 UTR, and coding region, respectively. Any
region prone to multiple microRNA targeting could not be
identiﬁed on CYCS and LOC100133737 genes. For all other
genes, the number of hotspots varies between 1 and 26. It
is anticipated that the genes that show the highest number
of hotspots possibly undergo highest sensitivity in miRNA
mediated regulation at transcriptional level because most
of the sensitive sites reside in the 5  regulatory domains
of the genes. Genes such as PINK1, UBE2J2, SEPT5, and
TH carried 26, 24, 23, 20 hotspots for miRNA action,
respectively. The details of miRNA target prone sites against
each gene are shown in Table S3. For example, in PINK1,
23 of the 26 sensitive target sites were found in the 5 UTR
region, 3 regions are found in CDS only. Surprisingly, no
hotspots could be identiﬁed in 3 UTR for PINK1. This
revealed that PINK1 is not prone to translational inhibition.
In reality, microRNA mediated transcriptional regulation is
lacking broadly in animals, but frequent is plants. Abun-
dance of predicted miRNA targets in the PINK1 regulatory
regions depicts complexity of microRNA mediated target
selection.
Conversely in UBE2J2, majority of such hotspots (19)
w e r ei d e n t i ﬁ e di n3  UTR while CDS region and 5 UTR
showed only 1 and 4 hotspots, respectively. Depending on
location of target sites, most likely UBE2J2 was regulated by
the translational initiation. These results show that miRNAs
can functionally target endogenous mRNAs in any region
including coding region and 5 UTR and not restricted to
the 3 UTR as described earlier. However, such dispersed
distribution of miRNA target can generate more complexity
inthenatureofinteraction,whichcounteractsthepossibility
of selection of most eﬃcient miRNA required for functional
knockdown of the PD genes.
3.3. Multiplicity and Cooperativity. In general term, one
miRNA can target more than one gene (multiplicity), and
one gene can be controlled by more than one miRNA
(cooperativity) [29]. As reported earlier single miRNA can
control hundreds of genes [43, 44]. Here, top 20 miRNAs
displaying high scores were initially selected. After assem-
bling all data, multiplicity and cooperativity were calculated.
From the dataset, miRNAs that displayed maximum number
of interactions with PD related genes were selected and
used for constructing an interaction map. miRNAs showing
maximum number of targets in PD related genes were
selected as top 10 miRNA. Maximum interactions were
found in 6 miRNAs, that is, hsa-miR-638, hsa-miR-1226
∗,
hsa-miR-612, hsa-miR-612, hsa-miR1469, hsa-miR-608 and
hsa-miR-939 that show high value of multiplicity. For
instance, hsa-miR-638 exhibited high multiplicity show-
ing total 119 interactions with 26 genes while no hsa-
miR-638 target sites were found on three genes, namely,
CASP3, PARK7, and SNCA. Defects in SNCA have been
implicated in the pathogenesis of Parkinson’s disease while
autosomal recessive mutations in PARK7 cause early onset
of Parkinson disease. CASP3 gene encodes a predominant
caspase involved in cleavage of amyloid-beta 4A precursor
protein, belonging to cysteine-aspartic acid protease (cas-
pase) family which is associated with neuronal death in
other neurological disorders. hsa-miR-1226
∗ displayed 107
interactions with 25 genes but no complementary target
sites could be identiﬁed for LOC100133737, PARK7, SNCA,
ubiquitinB. Therefore, it can be inferred that these miRNAs
may not be involved in regulation of activity of these
genes.
Similarly, we analyzed the same dataset for estimating
cooperativity.ItwasfoundthatPINK1,SEPT5,THexhibited
high cooperativity towards top 10 miRNAs. All top 10
miRNA displayed 974 targets on the selected genes. It pro-
v i d e sac o m p l e xp i c t u r ew h i c hi sd i ﬃcult to comprehend the
interactions. For example, PINK1 is regulated by 10 miRNAs
at 81 positions, so these top 10 miRNAs demonstrate high
cooperativity towards PINK1. Similarly, top 10 miRNAs
exhibited 79, 78 targets in SEPT5 and TH genes. In contrast,Journal of Biomedicine and Biotechnology 7
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Table 1: Multiplicity and cooperativity for all miRNA data.
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a less degree of cooperativity was found in LOC100133737,
SNCA genes suggesting a low sensitivity to, microRNA
mediatedregulation.Onlythreeof10microRNAthatis,hsa-
miR-638, hsa-miR-612, and hsa-miR-661 exhibited miRNA
targets on LOC10013373 (for details, see Table 1). Therefore,
multiplicity and cooperativity add more complexity of
microRNA selection and their sensitivity to large number of
t a r g e t so nP Dg e n e s .
Next,top10miRNAswerepredictedbasedonthehighest
scores. hsa-miR-612 showed the maximum score 212. All
the miRNAs having a score >=196 were selected and it was
found that 6 miRNAs were common among both datasets,
namely, miRNAs with the highest multiplicity and highest
scores.Basedon insilicoprediction, weanticipated thatthese
microRNAs may be master controller for regulating of PD
pathway genes.
3.4. Unique miRNA Targets. microRNA targeting a single
gene at single site can be termed as unique miRNA for
a particular dataset and holds much importance, being
speciﬁc towards a speciﬁc gene. Therefore, for targeting a
speciﬁc gene these microRNAs might be useful, but single
site targeting may not be suﬃcient to repress the activity of
that gene to a desired level. It was also found that only 100
of 866 miRNAs displayed single interaction with Parkinson
associated genes. Surprisingly, 3 out of 29 genes, SLC25A4,
SNCAIP, and ubiquitin, did not exhibit targets for these
unique miRNAs. They are not involved in single miRNA
mediated regulation. One more gene UBE1 that encodes
protein in the ﬁrst step of ubiquitin conjugation to mark
cellular proteins for degradation showed the highest no of
singlemiRNAtargetsimplyingtheneedofthehighestdegree
of speciﬁcity (Table S4 in Supplementary Material). These8 Journal of Biomedicine and Biotechnology
Table 2: Common microRNA target sites for various genes predicted using miRanda and TargetScan.
Gene microRNA
Start position
of target sites
predicted by
miRanda
End position
of target sites
predicted by
miRanda
Start position
of target sites
predicted by
TargetScan
End position
of target sites
predicted by
TargetScan
CASP9 hsa-miR-224 240 264 255 261
COX6B2
hsa-miR-138 676 701 693 699
hsa-miR-217 6 36 26 32
hsa-miR-339-5p 454 479 471 477
hsa-miR-492 274 293 285 291
hsa-miR-608 55 86 77 83
hsa-miR-661 163 187 180 186
hsa-miR-940 672 688 681 687
CYCS
hsa-miR-1301 1812 1840 1830 1836
hsa-miR-25 2191 2214 2204 2210
hsa-miR-510 2244 2273 2262 2268
hsa-miR-591 1332 1352 1341 1347
hsa-miR-658 2198 2232 2221 2227
hsa-miR-663 2283 2304 2286 2292
hsa-miR-769-5p 1943 1974 1964 1970
hsa-miR-939 1990 2018 2007 2013
APAF1 hsa-miR-650 639 662 654 660
PARK2
hsa-miR-361-3p 21 40 31 37
hsa-miR-574-5p 96 118 110 116
hsa-miR-614 263 291 282 288
SEPT 5
hsa-miR-1207-5p 643 664 657 663
hsa-miR-1250 671 696 687 693
hsa-miR-1825 600 622 614 620
hsa-miR-484 871 894 887 893
hsa-miR-572 877 899 880 886
hsa-miR-637 81 104 95 101
hsa-miR-663 160 183 176 182
hsa-miR-663b 74 93 86 92
SLC6A3
hsa-miR-1301 1613 1635 1626 1632
hsa-miR-193b 1518 1541 1533 1539
hsa-miR-331-3p 331 351 342 348
hsa-miR-34a 684 706 698 704
hsa-miR-449a 686 706 698 704
hsa-miR-486-3p 324 347 337 343
hsa-miR-601 406 432 423 429
hsa-miR-637 883 912 883 889
TH
hsa-miR-34c-5p 211 240 230 236
hsa-miR-658 217 245 236 242
hsa-miR-885-3p 96 115 108 114
hsa-miR-920 107 125 116 122
GBA
hsa-miR-1233 12 33 25 31
hsa-miR-212 363 386 376 382
hsa-miR-331-3p 109 133 124 130
hsa-miR-331-3p 159 178 169 175
hsa-miR-519e 4 26 18 24
hsa-miR-637 197 223 215 221
hsa-miR-661 452 476 467 473
hsa-miR-766 160 183 175 181Journal of Biomedicine and Biotechnology 9
results predict a coherent interplay between variation of
microRNA target and functional eﬃcacy of PD genes. It is
possible that simple computational prediction of microRNA
targets may shed some light on the behavior of target genes
involved in Parkinson disease.
3.5. Deciphering Complexity through miRNA and Gene Inter-
actions Map. To envisage the interrelationship of multiplic-
ity of top 10 miRNA and their association with selected
29 genes, a gene-miRNA interaction map for Parkinson
disease was constructed (Figure 5). Hsa-miR-612 showed
highest number of interactions against 19 genes while
four miRNAs hsa-miR-939, hsa-miR-1301, hsa-miR-1207-
5p, hsa-miR-1183 showed interactions with only 9 genes. In
contrast, counting the miRNA hits for individual gene, it
was found that UBE2L3 exhibited 9 interactions with top
scoring miRNAs whereas APAF1 and SNCA did not show
any interaction with these miRNAs. These genes might not
be under miRNA-based control. These ﬁndings suggest that
computer-based prediction of microRNA target selection
undoubtedly reduces the noise but is not suﬃcient to
estimateeﬃciencyofeachmicroRNAonthemultipletargets.
Next, several important physico-chemical properties
such as molecular weight (MW), free energy (δG in
Kcal/mole), and the sequence composition features for the
top ten miRNAs (based on multiplicity) were calculated
employing Oligo Calc: Oligonucleotide tool to identify any
potential speciﬁcity related to Parkinson’s disease. The size of
the miRNAs varied between 22 and 26 nucleotides. A narrow
range of diﬀerence in properties was found among top 10
miRNAs. All microRNAs displayed a high GC content with 2
miRNAs, namely, hsa-miR-1469 and hsa-miR-663 showing
exceptionally high GC composition of 91% (Table S5 in
supplement).GCandAUcontent%ofthehumanmiRNome
as taken from sequence feature statistics of 782 microRNAs
from Argonaute database [45] ranges from 19.05% to 95%
and 5 to 80.95%, respectively. The diﬀerence in properties is
not enough for preferential selection of one miRNA from the
others.
Finally, to investigate the sequence conservation of
microRNA, Multiple Sequence Alignment (MSA) available
at miRBase (http://microrna.sanger.ac.uk/)w a su s e d .Ac l e a r
predominance of G-nucleotide site at 20th position was
observed in all the top 10 miRNAs and a strong bias towards
G was also found at 8th, 12th, and 15th positions.
Intersection of miRanda and TargetScan prediction. In order
to verify our above-mentioned ﬁndings depicted exclusively
by miRanda, we have predicted only 3 UTR target sites using
TargetScan [46] since prediction of TargetScan is limited to
target sites only in 3 UTR. TargetScan relies on perfect seed
complementarity and thus reduces false positive rate. Target
sites predicted using miRanda and TargetScan were matched
and compared (Figure 6 and Table S6).
Two genes LOC100128525 and LOC100133737 in
Parkinson pathways were devoid of any predicted target sites
in the 3 UTR regions as predicted using both the algorithms.
Moreover, miRanda failed to predict target sites in PINK1
and SLC25A4 and resulted in prediction of target sites for
only 25 genes while TargetScan predicted target sites for all
remaining 27 genes. The number of targets sites predicted
by two separate programmes is quite large as compared to
common microRNA targets envisaged by both programmes.
Target sites predicted based on only seed sequence similarity
in TargetScan are greater than the 1588 sites predicted by
miRanda. However, intersection includes a small number
(142) of common target sites which is limited to only 12
genes (Table S7).
Using both algorithms, 7 microRNAs were predicted to
have target sites in vicinity. Target sites for 7 microRNAs,
namely, hsa-mir-138 (miRanda: 676–701, TargetScan: 693–
699),hsa-miR-217(miRanda:6–36,TargetScan:26–32),hsa-
miR-339-5p (miRanda: 454–479,TargetScan: 471–477), hsa-
miR-492 (miRanda: 274–293, TargetScan: 285–291), hsa-
miR-608 (miRanda: 55–86, TargetScan: 77–83), hsa-miR-
661 (miRanda: 163–187, TargetScan: 180–186), hsa-miR-940
(miRanda: 672–688, TargetScan: 681–687) were found in
speciﬁed region. Similar results were found for other 8 genes
and are summarized in Table 2.
Midbrain Speciﬁc microRNAs. The predicted microRNA
targets were also screened for a subset of microRNA
expressed in the midbrain. It comprises of 112 microRNAs.
In all, 378 target sites were predicted for 60 midbrain-
speciﬁcmiRNAsformiRandaacrosstheentirelengthofgene
(Table S8). Among them, 343 target sites were predicted
for 99 midbrain-speciﬁc microRNAs using TargetScan while
only 115 target sites were identiﬁed for 43 midbrain-speciﬁc
microRNAs using miRanda for 3 UTR (Tables S9 and S10
in Supplementary Material). Only 39 miRNAs were found
to be common in both algorithms for which 105 and 136
target sites were predicted by miRanda and TargetScan,
respectively. Only target sites for hsa-miR-138 in COX6B2
(miRanda: 676–701, TargetScan: 693–699) and hsa-miR-
25 in CYCS (miRanda: 2191–2214, TargetScan: 2204–2210)
were predicted to occur in close proximity. The variation in
resultscanbeattributedtodiﬀerenceinsetparametersintwo
independent algorithms.
4. Conclusion
Neurological disorders are complex diseases in which a
wealth of information remains hidden owing to a variety
of regulatory complexity. Despite of numerous studies on
Parkinson diseases, existence of multiple parallel pathways
or their convergence at a point is still a puzzle. The previous
studies have pointed out the role of miRNAs in the etiology
of PD. Absence of eﬃcient treatment methods tends us to
broaden our understanding of the candidate genes involved
in disease pathway. Knowledge of putative miRNA targets on
these genes achieved using fastcomputer-basedassayswillbe
a reasonable and powerful advancement for understanding
PD. Repression of candidate genes involved in pathogenesis
byasinglemiRNAoragroupofmiRNAsmayaidincombat-
ing this disease. In order to oﬀer a simplistic view of perplex-
ingrelationshipofgeneandmiRNAs,weproposeanintricate
and comprehensive microRNA-gene interaction map in the10 Journal of Biomedicine and Biotechnology
PD pathway. For gaining an insight about the mechanism
of these miRNA actions, distribution of these target sites at
diﬀerent regions was explored. Importantly, it was found
that miRNA target sites are not restricted only to 3 UTR
but are distributed across the entire length of gene. These
hotspots may be representing favored sites for miRNA-based
regulation. The miRNA and gene networks of a particular
trait are poorly understood. Interaction map also provides
a way for selecting important miRNAs markers required for
diagnosis and therapeutics. Finally, though physiochemical
properties of microRNA narrate some indicative parameters
yet it is not enough to understand the complex relationship
of Parkinson’s disease genes and microRNAs. The weakness
of the work is that as most of the computational miRNA
prediction algorithms focus on 3 UTR and a number of
miRNA in these search algorithms represent only a fraction
of total miRNA available in microRNA repositories like
miRBase, it is diﬃcult to validate the target sites for
those miRNAs and also in 5 UTR and CDS. Therefore,
computational prediction may not guide optimize selection
of any single microRNA for eﬃcient knock down and level
of action and further validation of these ﬁndings using
experimental approaches is required. Further analysis and
experimental validation of these results is mandatory for
resolvingcomplexityfortheselectionofmicroRNAtargetsin
future.
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